CA-INGRAM-MICRO
4.5.2021 14:05:12 CEST | Business Wire | Press release
Growing its Artificial Intelligence (AI) portfolio, Ingram Micro Inc. today announced an expanded, and now global, business relationship with UiPath , a leading enterprise automation software company and Robotic Process Automation (RPA) tech innovator.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005476/en/
RPA enables organizations in the digital transformation (DX) era to increase efficiency, workflow determinism, operation accuracy and compliance with regulations by automating repetitive and time-consuming mundane tasks. Additionally, software robots work to establish end-to-end automation across the organization while driving costs down. Ingram Micro’s broad and specialized Advanced Solutions portfolio began offering AI and RPA solutions a few years ago and has become one of the organization’s fastest-growing global practices.
“Robotic process automation is an important component within a company’s digital transformation game plan, and a great sales wedge for channel partners to introduce DX solutions and services into their existing end user customer base,” said Sabine Howest, vice president, global partner engagement and IoT, Ingram Micro Inc. “Using AI to automate repeatable, rules-driven processes is a practice companies of all sizes can benefit from and a growth opportunity we’re ready to drive with UiPath through our growing and global Advanced Solutions organization.”
“We’re thrilled that UiPath is offering additional support to high-value service providers like us through its new Ingram Micro program,” said Bhavyesh Virani, co-CEO of WonderBotz, a UiPath partner. “Ingram Micro’s global reach will help WonderBotz capture the rising demand for our custom services as well as for our prebuilt turnkey solutions for F&A professionals and healthcare, finance, banking, and hospitality leaders. The new UiPath/Ingram Micro program is an all-around win, enabling us to spend more time on delivering industry-leading client services.”
Ingram Micro’s relationship with UiPath started in India in 2018 and was quickly followed by China. Currently, the relationship is now expanded to North America and Latin America as well as Europe, Middle East, Africa, and the remainder of Asia Pacific. The team at Ingram Micro maintains a mature and dedicated UiPath team of experts who are here to help channel partners throughout the sales cycle including opportunity identification, design thinking, advisory services, licensing and training. With the support of Ingram Micro’s Centers of Excellence, channel partners selling UiPath benefit from shared best practices, “follow the sun” support services and global resources designed to meet the varied demands of the market locally, regionally, and globally.
“Ingram Micro and UiPath are partner-first organizations equally committed to continually investing in our partners to drive greater service differentiation, exceptional growth, and improved profitability,” says Thomas Hansen, Chief Revenue Officer, UiPath. “Enterprise automation is a category channel partners cannot ignore, and an investment enterprise organizations are making because of the immediate and measurable return on investment and improvement to the associate experience and the customer experience. We are thrilled to expand our successful relationship with Ingram Micro worldwide and look forward to helping channel partners capitalize on the market potential for RPA.”
In Q1 2021, the Forrester Wave™*: Robotic Process Automation named UiPath “a Leader” with the highest ranking in each of three categories: Current Offering, Strategy, and Market Presence. Additionally, UiPath Vice President of Global Alliances and Partners, Cheryln Chin, and Senior Vice President of Operations and Partners, Eddie O’Brien were recently named to the 2021 CRN Channel Chiefs list, along with eight Ingram Micro channel executives.
The entire UiPath portfolio is now available to Ingram Micro channel partners worldwide. To learn more about UiPath, contact your Ingram Micro partner manager. For Quote to order support, please email: UiPath-licensing@ingrammicro.com and for sales and pre-sales support, please email: UiPath-sd@ingrammicro.com .
*The Forrester Wave™: Robotic Process Automation, Q1 2021, March 15, 2021
About UiPath
UiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005476/en/
Link:
Social Media:
https://www.facebook.com/IngramMicroLatinAmericaDivision
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom